Comparison of Pathologic Response between Nivolumab- and Pembrolizumab-Based Neoadjuvant Chemoimmunotherapy in NSCLC: A Multi-Center Analysis

Yeong Jeong Jeon1, Tae Hee Hong2, Chang Young Lee2, Sehhoon Park3, Hong Kwan Kim1 1. Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea 2.Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea. 3.Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

첨부파일 : KTCVS_Abstract_regimen_수정.pdf

책임저자: Hong Kwan Kim

성균관대학교 삼성서울병원

발표자: Yeong Jeong Jeon, E-mail : yj.jeon.md@gmail.com